![]() ![]() Vanguard Group INC grew its stake in Masimo by 1.5% during the first quarter. Several hedge funds’ current ownership stakes in MASI have changed recently. Seven research analysts have given the stock of the firm a buy rating, while only two have given it a hold rating.Īccording to information from Bloomberg, the stock now has a consensus rating of “Moderate Buy” and an average target price of $182.00. ![]() Last, on March 1, Needham & Company LLC changed Masimo’s recommendation from “hold” to “buy” in a research report.Īlso, they increased their $192.00 price target from $173.00 for the stock. Piper Sandler raised their price target from $135.00 to $150.00 and assigned the stock a “neutral” rating in a research report released on March 1. ![]() Stifel Nicolaus raised its “buy” rating and price target for Masimo shares from $164.00 to $170.00 in a research note released on January 11.īTIG Research raised their target price for shares of Masimo from $180.00 to $195.00 in a research report published on March 1. Raymond James upgraded Masimo from “outperform” and raised their target price for the stock from $187.00 to $198.00 in a report on March 1. Many research analysts have recently released analyses on MASI shares. Masimo was valued at $515,000, according to the most recent Securities and Exchange Commission filing from Verus Capital Partners LLC (SEC). The institutional investor now owned 3,651 shares of the medical equipment supplier’s stock after acquiring 3,623 shares during the month. According to the latest Form 13F filing with the Securities and Exchange Commission, Verus Capital Partners LLC increased its holdings in Masimo Co (NASDAQ: MASI) by 12,939.3% during the third quarter (SEC).
0 Comments
Leave a Reply. |